# ACCENDRA HEALTH INC/VA/ (ACH) — Financial Analysis **Exchange:** NYSE **Coverage as of:** 2026-Q2 **Updated:** 2026-06-03 **Tier:** Free primer (step 2 of 19) **Sibling pages:** /stocks/ACH/thesis · /stocks/ACH/memo ## Financial Snapshot --- source: coverage-next-full ticker: ACH company: Accendra Health, Inc. step: "04" title: Financial Quality & Adversarial Research Sweep date: 2026-06-03 --- #### Executive Summary Four findings define financial quality at Accendra Health. First, revenue recognition is straightforward for a DME/home-health company — product sales at delivery, rental equipment monthly over the service period — but large non-GAAP adjustments ($189M in FY2025) obscure the GAAP picture significantly [S1]. Second, goodwill ($1,228M) represents 51% of total assets and carries material impairment risk following the $307M write-down already taken in FY2024 on the Apria segment [S2]. Third, cash flow quality is genuinely impaired by the capital intensity of the patient-service-equipment fleet: strict FCF (operating cash flow less all capex) is negative, and management's Non-GAAP FCF definition relies on a narrow capex exclusion to produce a positive $98M headline [S3]. Fourth, the DME industry carries endemic billing and audit risk — Medicare/Medicaid overpayment allegations, competitive-bidding disputes, and prior-authorization compliance are recurring themes — and Accendra inherits Apria's legacy exposure in addition to its own [S4]. --- #### 1. Statement Quality: Revenue Recognition ##### Revenue Recognition Policy Accendra Health (continuing operations = Patient Direct segment) recognizes revenue under two primary models [S1]: **Product sales (Byram Healthcare verticals: diabetes supplies, ostomy, wound care, urology):** Revenue recognized at the point of delivery to the patient, net of estimated returns and payer adjustments. Net revenue is recorded at the transaction price expected to be collected, reflecting contractual allowances, payer rate schedules, and prior-authorization compliance risk. **Rental / service revenue (Apria Healthcare: sleep therapy/CPAP equipment, respiratory therapy, home infusion):** Revenue recognized ratably over the service period — typically monthly — for equipment placed on rent with patients. Equipment is owned by Accendra and depreciated separately; the rental revenue stream is recurring and highly predictable once a patient is onboarded. CPAP/sleep therapy is the largest single revenue contributor. This two-model structure creates a favorable revenue quality profile: the rental book (predominantly Apria) is sticky, low-churn, and recurring; the product book (Byram) is episodic but highly repeat given chronic-condition patient populations (diabetics, ostomates). Both are third-party-payer-dominated (Medicare, Medicaid, commercial insurers), creating collectability risk but not unusual revenue recognition manipulation risk [S1]. ##### GAAP vs. Non-GAAP Reconciliation The gap between GAAP results and management's adjusted metrics is unusually wide for a company of this size [S1][S5]: | Item | FY2025 Amount | |------|--------------| | GAAP operating loss (continuing ops) | ~$(78)M | | Add: D&A | $214.5M | | Add: SBC | $12.9M | | Add: Acquisition/integration costs | ~$25M (est.) | | Add: Restructuring charges | ~$18M (est.) | | Add: Rotech termination fee | $80M | | Add: Other non-GAAP items | ~$16M (est.) | | **Adj. EBITDA (reported)** | **$374.8M** | The Rotech termination fee ($80M) is a one-time item that management adds back, which is defensible. However, acquisition/integration costs and restructuring charges have been recurring for three consecutive years (Apria was acquired in 2022), raising questions about whether these costs are truly non-recurring or structurally embedded in operating the combined business [S5]. Intangibles amortization of $74M (FY2025) vs. $40M (FY2024) is a mechanical increase from the Apria purchase price allocation; this is real economic dilution of the franchise over time — a buyer of the Apria customer relationships and trade names is effectively being charged through amortization as those assets age. Non-GAAP treatment adds this back, flattering Adj. EBITDA relative to true earning power [S1]. ##### Working Capital Dynamics **Days Sales Outstanding (DSO):** Management reports 12.4 days adjusted (reflecting the AR securitization/factoring program) and approximately 29.8 days excluding the off-balance-sheet AR program [S3]. The ~18-day difference represents receivables sold to the program — not collected, sold — which flatters the reported balance sheet. This is common in healthcare but important context: the true operating DSO is closer to 30 days, not 12. **Inventory days:** 17.8 days — lean, consistent with a distribution/DME model where most inventory is patient-specific product kits (diabetes test strips, ostomy supplies) with relatively short shelf lives. **Accounts payable:** Not explicitly broken out in available data, but AP turnover in DME companies is typically 30-45 days, creating a modest working capital advantage (paying suppliers in 30-45 days while collecting from payers in ~30 days). Supply chain disruptions remain a background risk given Byram's dependence on device and consumable manufacturers [S1]. --- #### 2. Accounting Adjustments ##### Goodwill Impairment History Accendra carries $1,228M in goodwill as of Q1 2026, down from approximately $1,535M at the time of the Apria acquisition in 2022 [S2]. The original Apria transaction created approximately $1.6B in goodwill, reflecting the premium paid for Apria's patient census, payer contracts, and DME license footprint. **FY2024: $307M goodwill impairment** on the Apria reporting unit. Trigger: persistent EBITDA shortfall versus acquisition underwriting, driven by Medicare reimbursement rate pressure, competitive bidding program headwinds, and the impact of GLP-1 drugs on CPAP demand — initially feared to reduce sleep apnea prevalence (though subsequent evidence shows net GLP-1 patients still require CPAP at high rates) [S2]. The remaining $1,228M goodwill is subject to annual impairment testing. Given FY2026 guidance calls for revenue to decline to $2.55-2.65B (from $2.76B in FY2025) and EBITDA to compress to $335-355M (from $375M), there is a real risk of another partial impairment if the business does not recover as projected. The discount rate environment (higher for longer) further pressures implied fair values in DCF-based impairment tests [S2]. ##### Intangibles Amortization Step-Up FY2024 intangibles amortization: ~$40M FY2025 intangibles amortization: ~$74M (a $34M increase) The increase reflects revised amortization schedules on Apria-origin intangibles — principally customer relationships and payer contracts — as purchase price accounting was finalized. This $74M charge is real economic cost over the life of the acquired intangibles; non-GAAP treatment inflates normalized earnings [S1]. ##### Discontinued Operations Classification The P&HS (Products & Healthcare Services) segment — the legacy Owens & Minor medical supply distribution business — was divested effective December 31, 2025. All FY2025 financial results for P&HS are classified as discontinued operations [S1][S5]. This creates year-over-year comparability challenges: FY2024 total revenue (as reported) included P&HS; the continuing-ops FY2024 Patient Direct revenue base is approximately $2,680M, creating the proper apples-to-apples comparator for FY2025's $2,762M. The $1.1B GAAP net loss in FY2025 includes substantial losses from P&HS discontinued ops — including probable write-downs on divested assets, wind-down costs, and tax effects of the divestiture [S5]. This is accounting noise that should not be extrapolated. --- #### 3. Adversarial Research Sweep *Note: No earnings call transcripts were used in this analysis. The following is based on SEC filings, public court records, regulatory databases, and reported news.* ##### Medicare/Medicaid Billing and DME Industry Audit Risk The DME (Durable Medical Equipment) industry is a perennial target of government oversight [S4][S6]. Key exposures for Accendra: **CPAP/Sleep Therapy Documentation Requirements:** CMS imposes strict prior-authorization and clinical documentation requirements for CPAP devices. Failure to maintain compliant documentation exposes providers to Medicare RAC (Recovery Audit Contractor) clawbacks. Apria, as one of the largest CPAP providers in the US, has historically faced documentation audits. CMS expanded CPAP prior-authorization programs in recent years, directly affecting Apria's operations and compliance costs [S4]. **Competitive Bidding Program:** CMS's DMEPOS Competitive Bidding Program sets reimbursement rates in covered geographic areas. Apria and Byram both operate in competitive-bid areas; bid selection and contract adherence are ongoing compliance requirements. Underbidding to win contracts and then underdelivering service quality is a known industry compliance issue [S4]. **OIG Work Plan:** The HHS Office of Inspector General has historically identified DME suppliers — particularly home oxygen and CPAP suppliers — as high-risk for overpayments. No specific ongoing investigation of Accendra is known to be publicly disclosed as of the research date, but the industry backdrop is high-audit [S6]. ##### Rotech Acquisition Termination In 2024, Accendra (then Owens & Minor) entered into a definitive agreement to acquire Rotech Healthcare, a major home respiratory and DME competitor, for approximately $1.36B [S7]. The transaction was terminated in 2025, with Accendra paying an $80M termination fee. **Why it failed:** The precise termination trigger is not fully public, but proximate causes reported include: (1) Accendra's deteriorating balance sheet and difficulty securing committed financing given its existing leverage and credit profile; (2) FTC antitrust scrutiny — the combined Apria + Rotech + Byram entity would have significant market concentration in CPAP and home oxygen in certain geographic markets; (3) Apria's underperformance relative to acquisition projections making additional leverage untenable [S7]. The $80M breakup fee was a significant cash outflow that accelerated the liquidity pressures now addressed by the May 2026 balance sheet restructuring. ##### SEC Enforcement and Restatements No active SEC enforcement actions against Accendra Health or its predecessor Owens & Minor are identified in publicly available records as of this research date [S4]. No accounting restatements in the lookback period. The 2024 goodwill impairment was disclosed proactively and is not an indicator of improper prior accounting — impairment reflects business performance shortfalls, not manipulation. ##### Litigation **Legacy Owens & Minor litigation:** As a large healthcare supply chain company, OMI historically faced product liability claims, pricing disputes with hospital systems, and employment-related litigation — all routine for companies of this scale [S4]. **Apria legacy litigation:** Apria carries contingent liabilities from pre-acquisition operations including government audits, billing disputes, and prior-authorization compliance matters. The extent of indemnified vs. assumed liabilities from the 2022 acquisition is disclosed in 10-K risk factors but total exposure is not quantified publicly [S4][S6]. **Class action / securities litigation risk:** The 2024 goodwill impairment and failed Rotech deal are potential triggers for shareholder litigation alleging inadequate disclosure of acquisition integration challenges. No such action is confirmed in public records as of research date, but the risk exists [S4]. ##### Commercial Payer Contract Termination The $322M commercial payer contract termination — the single largest item driving Q1 2026 revenue decline — is an arm's-length business dispute, not a regulatory action. However, its abruptness and scale raise questions about contract concentration risk: one payer relationship representing approximately 12% of annual revenue is a material dependency [S5]. --- #### 4. Cash Flow Quality ##### Operating Cash Flow (Continuing Operations) FY2025 operating cash flow from continuing operations: approximately $154M [S3]. This figure benefits from working capital management (the AR securitization program converts receivables to cash quickly) and non-cash add-backs (D&A of $214.5M, SBC of $12.9M). Cash interest paid is approximately $107M annually (based on $1.5B average debt at ~7% effective rate), and cash taxes are minimal given GAAP losses and deferred tax positions. ##### Patient Service Equipment Capex — The Crux Patient service equipment capex: $188.8M in FY2025 [S3]. This is the economically essential investment to maintain and expand the rental equipment fleet (CPAP machines, oxygen concentrators, ventilators, hospital beds, nebulizers). Without this spend, the rental revenue book shrinks. It is not optional capex. | FCF Definition | FY2025 Amount | |----------------|--------------| | Operating CF (continuing ops) | ~$154M | | Less: Total capex (~$191M) | $(191)M | | **Strict FCF (negative)** | **~$(37)M** | | Management Non-GAAP FCF | $98.3M | The ~$135M gap between strict FCF and Non-GAAP FCF reflects management's narrower capex definition in the Non-GAAP calculation (excluding growth capex, or classifying some equipment purchases differently). Investors should anchor to strict FCF — this is a capital-intensive business that currently does not generate free cash flow under standard definitions [S3]. --- #### 5. Red Flags and Green Flags ##### Red Flags 1. **Negative GAAP FCF:** Strict FCF approximately -$37M in FY2025. The company does not generate free cash after maintaining its equipment fleet [S3]. 2. **Altman Z-Score 0.39:** Deep in distress territory (<1.81). Negative equity is the primary driver [S2]. 3. **$581M current debt** as of Q1 2026 — before restructuring closes. Near-term liquidity crisis without successful execution [S2]. 4. **Negative stockholders' equity (-$465M):** Driven by acquisition goodwill exceeding book equity, compounded by accumulated losses [S2]. 5. **Non-GAAP adjustments of $189M+** obscure the GAAP earnings picture; recurring "one-time" items (integration, restructuring) span three years [S1][S5]. 6. **$80M wasted on Rotech termination fee:** Destroyed shareholder value and accelerated the balance sheet crisis [S7]. 7. **Revenue declining in FY2026:** $2.55-2.65B guidance vs. $2.76B FY2025 — a step-down driven by payer exit and no offsetting volume recovery yet [S5]. 8. **Goodwill at 51% of assets:** High impairment risk if performance misses guidance [S2]. 9. **DME industry audit risk:** Perennial exposure to government overpayment recovery actions [S4][S6]. 10. **Off-balance-sheet AR program:** True DSO is ~30 days, not the reported 12.4 days [S3]. ##### Green Flags 1. **Recurring revenue model:** CPAP/respiratory rental is monthly, sticky, and chronic-condition-driven — low churn once patients are onboarded [S1]. 2. **GLP-1 tailwind inflection:** Initial fears of GLP-1 eliminating CPAP demand have not materialized; evidence suggests GLP-1 users still require CPAP at high rates, and weight loss may actually improve CPAP therapy adherence [S4]. 3. **Census growth in high-value verticals:** Sleep +5.3% YoY, ostomy +8.6%, urology +8.3% — strong organic patient additions in the most defensible categories [S5]. 4. **Q1 2026 beat:** EPS of -$0.04 vs. -$0.09 estimate suggests management has good near-term visibility and is not over-promising [S5]. 5. **Pure-play DME after P&HS divestiture:** The remaining Patient Direct business has a cleaner, higher-margin profile than the legacy distribution/supply chain business [S1][S5]. 6. **Adj. EBITDA margin 13.6%:** Reasonable for a DME operator; interest coverage (EBITDA/interest) of ~3.5x is manageable if refinancing closes [S3]. 7. **Balance sheet restructuring proactively announced:** May 2026 refinancing (if executed) addresses the near-term maturity wall and buys meaningful runway [S2]. --- #### 6. Overall Financial Quality Assessment **Score: 4.5 / 10** **Rationale:** Accendra Health's underlying business economics are sound — a recurring-revenue DME/home-health model serving chronic-condition patients, with visible census growth, improving product mix toward higher-acuity categories, and real operating leverage potential. The business model deserves a 6-7 quality rating on its own. The score is pulled down by three structural problems: (1) the capital structure is deeply impaired with Altman Z-Score of 0.39, $581M of near-term maturities, and negative equity — the company is technically in financial distress; (2) cash flow quality is poor, with strict FCF negative and a large non-GAAP adjustment obscuring this reality; (3) goodwill represents 51% of assets with a recent $307M impairment already in the history and continued downside risk. The May 2026 restructuring, if successfully closed, upgrades this score by 0.5-1.0 points. If the restructuring fails or is delayed, the company faces a genuine liquidity crisis given $581M of current maturities. Financial quality at ACH is fundamentally binary: restructuring success → investable; restructuring failure → distress scenario. --- #### Source Index - [S1] Accendra Health, Inc. (ACH) — FY2025 Annual Report (Form 10-K), SEC EDGAR; revenue recognition policies, non-GAAP reconciliation, D&A and SBC disclosures. - [S2] ACH Form 10-K FY2025; goodwill impairment disclosures, balance sheet, Altman Z-Score proxy calculation; Q1 2026 Form 10-Q; stockholders' equity. - [S3] ACH FY2025 Cash Flow Statement (10-K); patient service equipment capex $188.8M; operating CF from continuing ops ~$154M; Non-GAAP FCF $98.3M per earnings release; DSO disclosures. - [S4] HHS OIG Work Plans — DME suppliers; CMS DMEPOS Competitive Bidding Program documentation; CMS CPAP prior-authorization program; general DME industry audit risk literature; public litigation dockets. - [S5] ACH Q1 2026 Earnings Release (May 2026); revenue by segment; EPS actuals vs. consensus; FY2026 guidance $2.55-2.65B revenue; payer contract termination disclosure; discontinued ops classification. - [S6] OIG Advisory Opinions on DME billing; CMS Medicare RAC audit activity; Apria Healthcare legacy compliance risk factors per ACH 10-K. - [S7] Public reporting on Owens & Minor / Rotech acquisition agreement (2024) and termination (2025); $80M termination fee per ACH FY2025 10-K; FTC competitive review background. ## Deeper Financial Analysis The fundamental tier ($1.00) adds 8 dimensions not included here: - Revenue Breakdown — segment revenue, geographic mix, product-line margins - Financial Trends — QoQ momentum, leading indicators, inflection points - Balance Sheet — debt structure, dilution risk, working capital dynamics - Capital Allocation — ROIC, buyback cadence, reinvestment efficiency - Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights - Competitive Positioning — market share, pricing power, peer benchmarks - Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop **API endpoint:** GET /api/v1/research/ACH/fundamental ## Navigation - Overview: /stocks/ACH - Financials (this page): /stocks/ACH/financials - Thesis: /stocks/ACH/thesis - Investment Memo: /stocks/ACH/memo - Coverage universe: /stocks